View this post on Instagram

 

A post shared by Shannon Miller OLY (@shannonmiller96)

She also urges patients to let loved ones step in. “Say, ‘I can’t do it all today,’” she writes — reminding women that it’s okay to move slower, hand off responsibilities, and stop pretending everything is fine.

“Let someone else carry the groceries, the kids, or the emotional load.”

These small shifts can make a big difference for anyone facing cancer, no matter where they are in their journey. After 15 years of survivorship, Miller’s voice carries weight — and her message resonates deeply.

As she told Parade, “Survivorship is a journey.” Her story is a powerful reminder to trust your instincts, advocate for your health, and honor the long road of healing.

‘I Did Not Listen to My Body’

Miller’s cancer journey began with symptoms so subtle they were easy to dismiss — especially as a new mother.

“I would have my favorite skirt that I would wear at a meeting, and I remember I couldn’t quite zip it up,” Miller recalled.

“I thought that was odd, especially because I had had some pretty significant weight loss. I had lost about eight pounds… But I had a baby, so I just assumed it was baby weight.”

“And then there were stomach aches. But again, I kind of thought it was dehydration and my body after the baby, and all those things. So those are some of the things that I did not listen to my body in a way that I should have,” Miller explained.

Ovarian cancer is notoriously difficult to detect early, often presenting with vague signs like bloating, pelvic discomfort, and digestive changes. Many cases originate in the fallopian tubes before spreading to the ovaries, making early diagnosis even more elusive.

Ovarian cancer is often diagnosed at an advanced stage. In fact, it has been called “the sleeping lion,” says Dr. Kimberly Resnick, gynecologic oncologist at MetroHealth in Cleveland, Ohio. “It’s hard, because 75% of women who walk into our office with ovarian cancer, unfortunately, are going to walk in with advanced-stage disease.”

Her reflections underscore a critical truth: cancer doesn’t end when treatment does. Survivorship brings its own set of challenges—ongoing scans, persistent anxiety, and the constant awareness of one’s body.

Getting Through Treatment, One Day at a Time

After her diagnosis, Miller underwent surgery and aggressive chemotherapy. In a previous interview with SurvivorNet, she said the nausea was one of the hardest parts of her journey, and that she often felt weak.

“I had swung around uneven bars for more than a decade, and now I couldn’t open a bottle of water,” Miller said, comparing the experience to the gravity she had defied as a gymnast.

She set small goals for herself to get through her treatment and took it all one day at a time.

“My goal on many days was to get up, get dressed, and walk twice around the dining room table. And if I did that, I could check the box, and that was a good day. I didn’t always get there, but that was the goal,” she said.

While she is now cancer-free, she said she still undergoes regular testing to make sure the cancer hasn’t returned.

“I still get tested twice a year, and there are still tough days. For the most part, I’m doing well, feel fantastic, and have no complaints. But testing days can bring anxiety. Every time you get a stomachache, you have to wonder: Did it come back? And that can get really difficult,” Miller explained to Sports Illustrated.

Since overcoming ovarian cancer, Miller has used her platform to spread awareness about the disease. She began by sharing her own story, hoping it would make an impact on other women.

What to Know About Ovarian Cancer Symptoms and Genetic Testing

Ovarian cancer often doesn’t cause noticeable symptoms until it has already reached its late stages, and the symptoms that do appear early on are easy to mistake for something else.

“Ovarian cancer does not have any specific symptoms,” Dr. Beth Karlan, a gynecologic oncologist at UCLA Medical Center, told SurvivorNet.

WATCH: Spotting Ovarian Cancer Symptoms

The symptoms of ovarian cancer may include the following, according to SurvivorNet experts.

• A feeling of bloating or fullness
• Pain in the pelvis or abdomen
• Nausea
• Vomiting
• Changes in bowel habits

Genetic testing—analyzing a patient’s DNA or biopsy tissue—can reveal critical insights about cancer: how it forms, how it behaves, and how best to treat it.

“There are certain cancer-causing genes that can be passed down from generation to generation,” explains Dr. Derrick Haslem, the director of medical oncology at Intermountain Healthcare in Salt Lake City.

As researchers uncover more about these inherited mutations, they’re not only pinpointing who might be most at risk—they’re also refining how cancers are detected and treated.

When it comes to ovarian cancer, this information is especially vital.

WATCH: What genetic testing reveals about your cancer?

“There are a lot of mutations that put people at a higher risk for ovarian cancer,” says Dr. Haslem. That’s why your medical team asks about your family history—because genetic red flags can run in families. “If you have a family history of ovarian cancer or breast cancer, that’s a really important thing to bring up with your healthcare provider.”

Mutations in the BRCA1 and BRCA2 genes are among the most common genetic links to ovarian cancer. Another factor, homologous recombination deficiency (HRD), can occur in women with BRCA mutations and further disrupts the cells’ ability to repair their DNA.

If you do have a strong family history, your doctor may recommend testing for BRCA mutations or other inherited syndromes like Lynch syndrome, which can also increase risk for ovarian, colorectal, and breast cancers.

Sometimes, testing positive for a high-risk mutation may lead to conversations about preventive steps. “If you were tested and you had that gene, then somebody might talk to you about prophylactic surgery to remove the ovaries and fallopian tubes,” says Dr. Haslem. This kind of preventive surgery can significantly reduce future cancer risk in those genetically predisposed.

Beyond risk assessment, genetic findings also guide treatment. “Certain chemotherapies and targeted therapies are much more effective in those types of cases,” Dr. Haslem adds. For example, PARP inhibitors—designed to block DNA repair in cancer cells—have shown strong results in patients with BRCA mutations and HRD.

Ultimately, genetic testing isn’t just about knowing your risk—it’s a tool that helps tailor treatment and potentially saves lives.

Ovarian Cancer Recurrence and Treatments to Help

Ovarian cancer recurrence happens in “almost 25 percent of cases with early-stage disease and in more than 80 percent with more advanced stages,” according to research published in the medical journal Gland Surgery. With recurrence a strong possibility for this disease, especially in the later stages of ovarian cancer, certain drug treatments to deal with it are giving many women hope.

Ovarian cancer is sub-categorized into two groups.

• Platinum-Sensitive Ovarian Cancer: Your cancer does not return for more than six months after treatment with platinum-based chemotherapies, like carboplatin and cisplatin.
• Platinum-Resistant Ovarian Cancer: Your cancer returns within six months of treatment with platinum-based chemotherapies, like carboplatin and cisplatin.

“The mechanism that causes platinum resistance will cause someone to be resistant to other chemotherapies, as well. That’s why we’re looking for what we call targeted therapies – precision medicine,” Dr. Noelle Cloven from Texas Oncology-Fort Worth Cancer Center explained.

RELATED: Recurrent Ovarian Cancer Treatment: Is Your Disease “Platinum-Sensitive”?

Targeted therapies, or precision medicine, specifically target the proteins that control cancer cells’ growth, division, and spread.

Maintenance Therapy for Ovarian Cancer

Maintenance therapy plays a critical role in helping ovarian cancer patients stay in remission after completing their initial treatment, which often includes surgery and chemotherapy.

“Maintenance therapy is continued treatment after the patient finishes their initial treatment,” explains Dr. Alpa Nick, a gynecologic oncologist with Tennessee Oncology in Nashville.

WATCH: PARP inhibitors are now options as part of ovarian cancer treatment for a growing number of women.

One common form of maintenance therapy is a daily oral medication known as a PARP inhibitor, which works by preventing cancer cells from repairing their DNA.

“The biggest question is: How do you choose between bevacizumab (brand name, Avastin) or a PARP inhibitor for maintenance therapy?” Dr. Nick says.

Both are effective options, but they take very different approaches. While PARP inhibitors target cancer cells’ internal repair systems, Avastin works externally by blocking new blood vessel growth, essentially starving tumors of the nourishment they need.

Genetic testing is key to determining which treatment is most effective. “When patients have their surgery, we can test their tumor to decide if their tumor has a homologous recombination deficiency (HRD),” says Dr. Nick. If HRD is present, patients are more likely to benefit from PARP inhibitors.

Some women may be candidates for a combination approach. The Food and Drug Administration (FDA) has approved Avastin in combination with olaparib (brand name Lynparza) for women with HRD-positive tumors who respond to platinum-based chemotherapy.

This pairing increased progression-free survival in clinical trials from 17 to 37 months. “A patient really has to make a decision upfront, or near the beginning of their treatment, that they want bevacizumab maintenance treatment because they’ll have it with their primary chemotherapy,” adds Dr. Nick.

American Society of Clinical Oncology (ASCO) guidelines now recommend that PARP inhibitors be offered to women newly diagnosed with stage III or IV ovarian cancer, regardless of their genetic status, if they’ve responded well to chemotherapy.

Meanwhile, another breakthrough therapy is offering new hope for patients with platinum-resistant ovarian cancer: Elahere (mirvetuximab). This targeted treatment is designed for women who test positive for high levels of folate receptor-alpha (FRα), a molecular marker found on some ovarian cancer cells.

“What that means is that the antibody part of the drug conjugate binds to the folate receptor on the tumor cells, and then that gets taken up into the tumor cell,” says Dr. Lyons.

“And then the drug that is conjugated with is the part that actually kills the tumor cells, by affecting the tumor cells’ ability to divide.” Often described as “biological missiles,” these antibody-drug conjugates are ushering in a new age of precision therapy.

Ovarian Cancer Recurrence

When cancer returns, it is referred to as recurrence. It often occurs because some cancer cells are left behind after treatment. Those cells grow over time and are eventually detected in follow-up scans received by patients in remission.

Ovarian cancer patients faced with a recurrence will likely need to restart chemotherapy or consider another surgical procedure.

WATCH: Ovarian cancer recurrence.

The type of treatment recommended for recurrence can depend on several factors:

• The period within which the cancer recurred
• The kind of chemotherapy the woman underwent in the past
• Side effects that came as a result of past treatments
• The length of time between the last treatment the woman underwent and the recurrence
• The specific mutations and molecular features of your cancer

If a woman’s time between remission and recurrence is more than six months, then the ovarian cancer is categorized as “platinum-sensitive” (that is, responsive to a platinum-based chemotherapy treatment), and that patient will be treated with chemotherapy and another platinum-based drug.

If the recurrence happens less than six months into remission, the ovarian cancer is classified as “platinum-resistant.” At that point, women are usually treated with another type of chemotherapy and encouraged to enter into a clinical trial. Alternatively, women might be platinum-refractory, which refers to a disease that grows while the patient is on chemotherapy and has a particularly poor prognosis.

Determining the probability that a woman’s cancer will recur depends on the stage at which she was initially diagnosed. According to most data:

• Women with stage 1 ovarian cancer have a 10 percent chance of recurrence.
• Women in stage 2 have a 30 percent chance of recurrence.
• Women in stage 3 have a 70 to 90 percent chance of recurrence.
• Women in stage 4 have a 90 to 95 percent chance of recurrence.

WATCH: Clinical trials can be life-saving.

Clinical trials are an option for women facing ovarian cancer with a high probability of recurrence. If you fall into this category, ask your doctor about possible eligibility for a clinical trial.

Clinical trials help doctors better understand cancer and discover more effective treatment methods. They also allow patients to try a treatment before it’s approved by the U.S. Food and Drug Administration (FDA), a potentially life-changing option.

Questions for Your Doctor

If you have been diagnosed with ovarian cancer and need guidance to further educate yourself on the disease and treatment, consider these questions for your doctor.

• What type of ovarian cancer do I have?
• What stage is my cancer in?
• Do you recommend I get genetic testing for any gene mutations, such as BRCA mutations?
• What initial treatment options do you recommend?
• What are the possible side effects of the recommended treatment, and how can they be coped with?
• Will insurance help cover my recommended treatment?

Learn more about SurvivorNet's rigorous medical review process.